Jan 29- Biogen Idec Inc said on Wednesday its new, high-profile oral multiple sclerosis drug Tecfidera had sales of $398 million in the fourth quarter, easily exceeding estimates for a third successive quarter and keeping it on track to top $1 billion in its first year on the market.
Jan 29- Biogen Idec Inc on Wednesday said fourth-quarter profit soared 57 percent, helped by strong sales of its new multiple sclerosis drug, Tecfidera. The U.S. biotechnology company's net profit rose to $457.3 million, or $1.92 per share, in the quarter ended Dec. 31, from $292.1 million, or $1.23 per share, a year earlier.
Some of Tuesday's midday movers:
“These are the kind of stocks you can fall back on, in moments where the market gets clobbered,” said Cramer.
Are you prepared to navigate another wave of selling, should one come, in the week ahead?
The jobs report may have changed the landscape, entirely. That makes next week's earnings all the more critical.
Some of Thursday's midday movers:
Jan 9- Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders in a deal for up to $320 million. Sangamo shares jumped as much as 30 percent to a six-year high of $17.73 on the Nasdaq on Thursday morning.
Jan 9- Sangamo Biosciences Inc said it would collaborate with Biogen Idec Inc to develop treatments for a group of inherited blood disorders. Sangamo shares rose about 8 percent to $14.74 in premarket trading.
*FDA asks for more clinical trials on Lemtrada. The FDA also demanded Sanofi carry out further clinical trials using different designs and methods prior to approval, Sanofi said.
Sanofi's Lemtrada multiple sclerosis treatment has failed to win approval from U.S. regulators, dealing a setback to a drug which was at the heart of the French drugmaker's $20 billion takeover of biotech firm Genzyme.
Time to revisit some of Cramer's top themes. Are they still investable?
Some of Monday's midday movers:
Dec 2- Biogen Idec Inc on Monday said the U.S. Food and Drug Administration will extend by three months its deadline for reviewing the company's experimental long-acting medicine for hemophilia.
Some of Monday's midday movers.
If you can move somewhat swiftly, Cramer thinks 4 stocks present opportunity right here, right now.
*Biogen, Gilead lead health-sector rally on news from Europe. NEW YORK, Nov 22- U.S. stocks rose on Friday, with the S&P 500 closing above 1,800 for the first time and healthcare names leading the way higher.
NEW YORK, Nov 22- U.S. stocks rose on Friday, led by healthcare stocks, putting the Dow and S&P 500 on track for a seventh straight week of gains. Shares of Biogen shot up 11.9 percent on heavy volume to $282.37 after the company won 10 years of exclusivity protection for its multiple sclerosis drug, Tecfidera, from regulators in Europe.
NEW YORK, Nov 22- U.S. stocks edged higher on Friday in the absence of economic data and ahead of a holiday-shortened week in the United States, a day after the Dow industrials closed above 16,000 for the first time.
Friday's midday movers.